Release date: 2026-10-21 13:51:53 Recommended: 3
As monotherapy for adult patients with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm), HER2-negative locally advanced or metastatic breast cancer; in combination with enzalutamide